Literature DB >> 19434740

Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine.

Lydia Lee1, Mouhamad Alloosh, Romil Saxena, William Van Alstine, Bruce A Watkins, James E Klaunig, Michael Sturek, Naga Chalasani.   

Abstract

UNLABELLED: Miniature pigs residing in the Ossabaw Island (Ossabaw pigs) exhibit a thrifty genotype, and when fed a high-calorie diet they consistently develop metabolic syndrome defined by obesity, insulin resistance, hypertension, and dyslipidemia. We conducted a study to induce steatohepatitis in Ossabaw pigs by dietary manipulation. Pigs were fed standard chow (controls, n = 15), high-fructose diet (20% kcal from fructose and 10.5% kcal from fat) (fructose group, n = 9), atherogenic diet (20% kcal from fructose and 46% kcal from fat and 2% cholesterol and 0.7% cholate by weight) (atherogenic diet group, n = 13), and modified atherogenic diet (different source of fat and higher protein but lower choline content) (M-Ath diet group, n = 7). All animals were sacrificed at 24 weeks after dietary intervention. The high-fructose group had significant weight gain, hypertension, and insulin resistance but showed normal liver histology. The atherogenic diet group had metabolic syndrome and abnormal liver histology consisting of significant microvesicular steatosis and fatty Kupffer cells but no ballooning or fibrosis. The M-Ath diet group developed severe metabolic syndrome and markedly abnormal liver histology with macrovesicular and microvesicular steatosis, fatty Kupffer cells, extensive hepatocyte ballooning, and pericellular/perisinusoidal fibrosis. Compared with controls, the M-Ath diet group had significantly lower serum adiponectin but higher serum leptin and tumor necrosis factor (TNF) levels and higher hepatic triglyceride and malondialdehyde levels.
CONCLUSION: Ossabaw pigs fed a modified atherogenic diet develop severe metabolic syndrome and abnormal liver histology with close resemblance to human nonalcoholic steatohepatitis (NASH).

Entities:  

Mesh:

Year:  2009        PMID: 19434740      PMCID: PMC3254146          DOI: 10.1002/hep.22904

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  31 in total

1.  Antioxidant activity applying an improved ABTS radical cation decolorization assay.

Authors:  R Re; N Pellegrini; A Proteggente; A Pannala; M Yang; C Rice-Evans
Journal:  Free Radic Biol Med       Date:  1999-05       Impact factor: 7.376

2.  A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.

Authors:  Gianluca Svegliati-Baroni; Cinzia Candelaresi; Stefania Saccomanno; Gianna Ferretti; Tiziana Bachetti; Marco Marzioni; Samuele De Minicis; Liliana Nobili; Renata Salzano; Alessia Omenetti; Deborah Pacetti; Soeren Sigmund; Antonio Benedetti; Alessandro Casini
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

3.  Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats.

Authors:  Won-Il Jeong; Da-Hee Jeong; Sun-Hee Do; Yoo-Kyeong Kim; Ho-Yong Park; Oh-Deog Kwon; Tae-Hwan Kim; Kyu-Shik Jeong
Journal:  J Vet Med Sci       Date:  2005-03       Impact factor: 1.267

4.  Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation.

Authors:  M D Weltman; G C Farrell; C Liddle
Journal:  Gastroenterology       Date:  1996-12       Impact factor: 22.682

5.  Dietary ratio of n-6/n-3 PUFAs and docosahexaenoic acid: actions on bone mineral and serum biomarkers in ovariectomized rats.

Authors:  Bruce A Watkins; Yong Li; Mark F Seifert
Journal:  J Nutr Biochem       Date:  2005-06-21       Impact factor: 6.048

Review 6.  Mechanisms of disease progression in nonalcoholic fatty liver disease.

Authors:  Janice Jou; Steve S Choi; Anna Mae Diehl
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

7.  Soy protein ameliorates metabolic abnormalities in liver and adipose tissue of rats fed a high fat diet.

Authors:  Ivan Torre-Villalvazo; Armando R Tovar; Victoria E Ramos-Barragán; Marco Antonio Cerbón-Cervantes; Nimbe Torres
Journal:  J Nutr       Date:  2008-03       Impact factor: 4.798

8.  The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance.

Authors:  Mary E Rinella; Richard M Green
Journal:  J Hepatol       Date:  2004-01       Impact factor: 25.083

9.  Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression.

Authors:  Laurent Vergnes; Jack Phan; Merav Strauss; Sherrie Tafuri; Karen Reue
Journal:  J Biol Chem       Date:  2003-08-15       Impact factor: 5.157

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  95 in total

1.  Challenging the rodent hegemony: a new rabbit model of nonalcoholic steatohepatitis.

Authors:  Jaideep Behari; Naga Chalasani
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

2.  Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.

Authors:  Michael Charlton; Anuradha Krishnan; Kimberly Viker; Schuyler Sanderson; Sophie Cazanave; Andrea McConico; Howard Masuoko; Gregory Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

Review 3.  Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame.

Authors:  Samar H Ibrahim; Petra Hirsova; Harmeet Malhi; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2015-12-01       Impact factor: 3.199

4.  Age- and Sex-Associated Effects on Acute-Phase Proteins in Göttingen Minipigs.

Authors:  Berit Ø Christoffersen; Søren J Jensen; Trine P Ludvigsen; Sara K Nilsson; Anette B Grossi; Peter M H Heegaard
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

5.  Effect of metabolic syndrome and aging on Ca2+ dysfunction in coronary smooth muscle and coronary artery disease severity in Ossabaw miniature swine.

Authors:  Jill K Badin; Rebecca S Bruning; Michael Sturek
Journal:  Exp Gerontol       Date:  2018-05-03       Impact factor: 4.032

6.  Shock wave lithotripsy targeting of the kidney and pancreas does not increase the severity of metabolic syndrome in a porcine model.

Authors:  Rajash K Handa; Andrew P Evan; Bret A Connors; Cynthia D Johnson; Ziyue Liu; Mouhamad Alloosh; Michael Sturek; Carmella Evans-Molina; Jessica A Mandeville; Ehud Gnessin; James E Lingeman
Journal:  J Urol       Date:  2014-03-18       Impact factor: 7.450

7.  Enhanced skeletal muscle growth in myostatin-deficient transgenic pigs had improved glucose uptake in stretozotocin-induced diabetes.

Authors:  Biao Li; Wentao Cui; Jinzeng Yang
Journal:  Transgenic Res       Date:  2020-02-20       Impact factor: 2.788

8.  Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.

Authors:  Gabriella V Hernandez; Victoria A Smith; Megan Melnyk; Matthew A Burd; Kimberly A Sprayberry; Mark S Edwards; Daniel G Peterson; Darin C Bennet; Rob K Fanter; Daniel A Columbus; Juan P Steibel; Hunter Glanz; Chad Immoos; Margaret S Rice; Tasha M Santiago-Rodriguez; Jason Blank; Jennifer J VanderKelen; Christopher L Kitts; Brian D Piccolo; Michael R La Frano; Douglas G Burrin; Magdalena Maj; Rodrigo Manjarin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-31       Impact factor: 4.052

Review 9.  Implications of diet on nonalcoholic fatty liver disease.

Authors:  Shelby Sullivan
Journal:  Curr Opin Gastroenterol       Date:  2010-03       Impact factor: 3.287

Review 10.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.